Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Antipsychotics TDM market size was valued at US$ 222,1 million in 2022 and is poised to grow at a significant CAGR of 5.8% over 2023-2029. Antipsychotic pharmaceuticals are medications that are used to treat psychosis, such as schizophrenia and bipolar illness. Psychosis is a serious sign of a mental disease that includes a loss of touch with reality, which affects how one processes information. On the basis of drug type, the risperidone segment is anticipated to hold the major market revenue share in the forecasting market because Risperidone is a medication that is used to treat a variety of mental and emotional problems (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder).
This drug can assist you in thinking clearly and participating in daily activities. Moreover, in Feb 2019 Indivior PLC launched of once-monthly PERSERI (risperidone) for extended-release injectable suspension in the United States. PERSERIS is approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. PERSERIS delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended., Antipsychotic medicine demand is increasing as the prevalence of psychosis and associated disorders rises. Genetic abnormalities, substance-induced psychoses, and physical sickness leading to depression are some of the key causes contributing to the rising prevalence of these disorders.
Study Period
2024-2030Base Year
2023CAGR
5.8%Largest Market
North AmericaFastest Growing Market
North America
A key growth driver for the market is the rising frequency of mental health diseases such as schizophrenia and bipolar disorder among the population. Anxiety disorders are the most frequent mental ailment in the United States, impacting 40 million persons aged 18 and over, or 18.1 percent of the population each year, according to the Anxiety and Depression Association of America. Anxiety disorders affect about half of the persons who have been diagnosed with depression.
North America accounted to have the highest share in the global antipsychotics market and the market is expected to grow at a significant CAGR over the forecast years owing to the nations in this area, there is a well-established healthcare infrastructure, a superior regulatory framework, and government assistance. There is a growing public awareness of psychotic illnesses and other related conditions including mania, anxiety, and depression. The market is predicted to develop due to increased access and availability of drugs for the treatment of mental illnesses.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2022 |
US$ 222,1 million |
|
Market CAGR |
5.8% |
|
By Drug Type |
|
|
By Technology Type |
|
|
By Region |
|
Download Free Sample Report
The antipsychotics tdm market is projected to expand at a CAGR of 5.8% during the forecast period.
Roche Diagnostics, Sekisui Diagnostics, Thermo Fischer Scientific, Beckman Coulter, ChromSystems
Asaia Pacific is the fastest-growing region for antipsychotics tdm market
| 1.Executive Summary |
| 2.Global Antipsychotics TDM Market Introduction |
| 2.1.Global Antipsychotics TDM Market - Taxonomy |
| 2.2.Global Antipsychotics TDM Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Technology Type |
| 2.2.3.Region |
| 3.Global Antipsychotics TDM Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Antipsychotics TDM Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Antipsychotics TDM Market By Drug Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Aripiprazole |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Clozapine |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Haloperidol |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Olanzapine |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Ziprasidone |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Chlorpromazine |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Lithium |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Lurasidone |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Paliperidone |
| 5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 5.10. Perphenazine |
| 5.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.10.3. Market Opportunity Analysis |
| 5.11. Quetiapine |
| 5.11.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.11.3. Market Opportunity Analysis |
| 5.12. Risperidone |
| 5.12.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.12.3. Market Opportunity Analysis |
| 6.Global Antipsychotics TDM Market By Technology Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Immunoassay |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. LC-MS/MS |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. GC-MS/MS |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Antipsychotics TDM Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Aripiprazole |
| 8.1.2.Clozapine |
| 8.1.3.Haloperidol |
| 8.1.4.Olanzapine |
| 8.1.5.Ziprasidone |
| 8.1.6.Chlorpromazine |
| 8.1.7.Lithium |
| 8.1.8.Lurasidone |
| 8.1.9.Paliperidone |
| 8.1.10.Perphenazine |
| 8.1.11.Quetiapine |
| 8.1.12.Risperidone |
| 8.2. Thiothixene Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Immunoassay |
| 8.2.2.LC-MS/MS |
| 8.2.3.GC-MS/MS |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Aripiprazole |
| 9.1.2.Clozapine |
| 9.1.3.Haloperidol |
| 9.1.4.Olanzapine |
| 9.1.5.Ziprasidone |
| 9.1.6.Chlorpromazine |
| 9.1.7.Lithium |
| 9.1.8.Lurasidone |
| 9.1.9.Paliperidone |
| 9.1.10.Perphenazine |
| 9.1.11.Quetiapine |
| 9.1.12.Risperidone |
| 9.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Immunoassay |
| 9.2.2.LC-MS/MS |
| 9.2.3.GC-MS/MS |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 9.3.7. |
| 10.Asia Pacific (APAC) Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Aripiprazole |
| 10.1.2.Clozapine |
| 10.1.3.Haloperidol |
| 10.1.4.Olanzapine |
| 10.1.5.Ziprasidone |
| 10.1.6.Chlorpromazine |
| 10.1.7.Lithium |
| 10.1.8.Lurasidone |
| 10.1.9.Paliperidone |
| 10.1.10.Perphenazine |
| 10.1.11.Quetiapine |
| 10.1.12.Risperidone |
| 10.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Immunoassay |
| 10.2.2.LC-MS/MS |
| 10.2.3.GC-MS/MS |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Aripiprazole |
| 11.1.2.Clozapine |
| 11.1.3.Haloperidol |
| 11.1.4.Olanzapine |
| 11.1.5.Ziprasidone |
| 11.1.6.Chlorpromazine |
| 11.1.7.Lithium |
| 11.1.8.Lurasidone |
| 11.1.9.Paliperidone |
| 11.1.10.Perphenazine |
| 11.1.11.Quetiapine |
| 11.1.12.Risperidone |
| 11.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Immunoassay |
| 11.2.2.LC-MS/MS |
| 11.2.3.GC-MS/MS |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Aripiprazole |
| 12.1.2.Clozapine |
| 12.1.3.Haloperidol |
| 12.1.4.Olanzapine |
| 12.1.5.Ziprasidone |
| 12.1.6.Chlorpromazine |
| 12.1.7.Lithium |
| 12.1.8.Lurasidone |
| 12.1.9.Paliperidone |
| 12.1.10.Perphenazine |
| 12.1.11.Quetiapine |
| 12.1.12.Risperidone |
| 12.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Immunoassay |
| 12.2.2.LC-MS/MS |
| 12.2.3.GC-MS/MS |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Roche Diagnostics |
| 13.2.2.Sekisui Diagnostics |
| 13.2.3.Thermo Fischer Scientific |
| 13.2.4.Beckman Coulter |
| 13.2.5.ChromSystems |
| 13.2.6.Abbott Diagnostics |
| 13.2.7.Siemens Healthineers |
| 13.2.8.SJK Global, LLC. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.